• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Dacomitinib may be effective in EGFR-associated lung cancer

byKhang DinhandDavid Wang
November 8, 2014
in Oncology, Pulmonology
Reading Time: 3 mins read
Dacomitinib may be effective in EGFR-associated lung cancer
Share on FacebookShare on TwitterShare on LinkedIn

1. Patients with advanced EGFR-associated non-small-cell lung cancer treated with dacomitinib had increased progression-free survival as compared to those without mutations.

2. Common adverse side effects including diarrhea, dermatitis, dry skin, and stomatitis were comparable to those of first generation tyrosine kinase inhibitors.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Tyrosine kinase inhibitors (TKI) of endothelial growth factor receptor (EGFR) have previously been shown to significantly increase progression-free survival in patients with EGFR-mutant, non-small-cell lung cancer (NSCLC). Despite this, no difference in overall survival has been demonstrated with EGFR inhibitors, in large part due to tumor cells’ ability to develop escape mutations that bypass EGFR. Dacomitinib is a second generation TKI which is both an irreversible inhibitor of EGFR and a pan-inhibitor of the accessory human epidermal growth factor receptor (HER) pathway. The purpose of this trial was to evaluate the role of dacomitinib as first-line therapy in patients with EGFR-associated NSCLC.

In this phase II trial, 89 treatment-naïve NSCLC patients with either molecular or clinical characteristics associated with TKI response were given dacomitinib as first line therapy. The results demonstrated a significantly increased 4-month progression-free survival rate in the EGFR-mutant population versus the non-mutated cohort.  Interestingly, the estimated median progression-free survival for the favorable EGFR mutated group was over 40 months, which was significantly longer than prior studies using afatinib, another second generation EGFR inhibitor that does not have HER activity. The safety of dacomitinib were comparable in both frequency and severity to adverse events of currently used first-generation EGFR inhibitors. The results of this trial support the use of dacomitinib as first-line therapy for EGFR-associated NSCLC. However, limitations of this study included its relatively short median follow up time of 24.8 months, small patient population, and lack of randomized comparisons to first-generation EGFR inhibitors.

Click to read the study in The Lancet Oncology

RELATED REPORTS

Optune Mya is not approved for brain metastases from non-small cell lung cancer in topline regulatory results

Ivonescimab plus chemotherapy produced major and complete pathological responses in resectable NSCLC in a phase II study

Relevant reading: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

FDA approvedFor non-small cell lung cancer: Jideytro (zidesamtinib), Jul 22, 2026→

In-Depth [randomized controlled trial]: In this multicenter, open-label, phase II trial, 45 patients with favorable EGFR mutation status and 44 with unknown mutation status and clinical characteristics predicting response to TKI, were given dacomitinib as first-line therapy. Progression-free survival at 4 months was the primary endpoint.  In patients with EGFR mutations, 95% met the 4 month criteria for progression-free survival (95% CI: 83.2-98.9%), while 68.2% of patients with unknown EGFR mutation status met the criteria (95% CI: 44.6-83.4%). In patients with known EGFR wild-type status, only 33.3% were progression free at 4 months (95% CI: 10.9-58.0%). This result corresponded to an estimated overall survival of 40.2 months (95% CI: 29.0-not reached), 24.3 months (95% CI: 19.0-35.1), and 19.7 months (95% CI: 3.5-24.3), respectively.  The most common adverse events were diarrhea in 83 patients, dermatitis in 69 patients, dry skin in 39 patients, and stomatitis in 36 patients. The majority of these side effects were mild in nature. The null hypothesis of progression-free survival of 50% or less at 4 months was tested using the Kaplan-Meier method in a Fleming single-stage trial design.

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer, Escalated-dose radiotherapy did not increase survival in prostate cancer, Stereotactic radiosurgery promising for patients with multiple brain metastases

Image: CC/Yale Rosen

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

 

Tags: DacomitinibEGFR tyrosine kinase inhibitorsnon-small cell lung cancer
Previous Post

Cholesterol-containing lipid particles protect mice from lethal bacterial toxins

Next Post

Olaparib monotherapy may be effective in advanced BRCA-associated cancers

RelatedReports

Large cell carcinoma collage of an older man beside engraved lungs with a cobalt patch, a blank CT film and a potted fern
2MM Trial Briefs

Optune Mya is not approved for brain metastases from non-small cell lung cancer in topline regulatory results

November 12, 2026
Lung cancer collage: engraved lungs with the trachea and branching bronchi above a knitted wool scarf and a pine sprig
2MM Trial Briefs

Ivonescimab plus chemotherapy produced major and complete pathological responses in resectable NSCLC in a phase II study

November 6, 2026
Lung cancer collage: engraved lungs with the trachea and branching bronchi above a knitted wool scarf and a pine sprig
Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026
Lung cancer collage: engraved lungs with the trachea and branching bronchi above a knitted wool scarf and a pine sprig
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Next Post
Olaparib monotherapy may be effective in advanced BRCA-associated cancers

Olaparib monotherapy may be effective in advanced BRCA-associated cancers

Collage on colposcopy: a colposcope on a stand, a clinic gown on a hook, a cotton swab and a magnifying lens

Patient Basics: Colposcopy

Rixtuximab superior to azathioprine in autoimmune vasculitis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.